|
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study -Pub
|
|
1
|
199
|
July 31, 2024
|
|
Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity
|
|
1
|
131
|
July 30, 2024
|
|
Using the relative potency comparison approach, Powley et al have demonstrated the safety of NTTP exposures at or above levels of 1500 ng/day
|
|
1
|
248
|
July 30, 2024
|
|
Nitrosamine Contamination of Pharmaceuticals: Cases in Japan, Formation Mechanisms, Detection Methods, Regulatory Perspectives, and Insights -Pub
|
|
1
|
154
|
July 30, 2024
|
|
How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits
|
|
0
|
120
|
July 26, 2024
|
|
Leveraging ICH M7 Control Options 3 and 4: Discussion and Clarification Using Industrial Case Studies -Pub
|
|
0
|
522
|
July 23, 2024
|
|
Quantum Mechanical Assessment of Nitrosamine Potency -Pub
|
|
3
|
422
|
July 15, 2024
|
|
AZIDO Impurities Topic
|
|
4
|
1263
|
July 11, 2024
|
|
A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies -Pub
|
|
0
|
165
|
July 10, 2024
|
|
Non-mutagenic, carcinogenic impurities
|
|
3
|
487
|
June 30, 2024
|
|
Discussion on Cleaning Validation Requirements for Nitrosamines
|
|
3
|
955
|
June 24, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
186
|
June 13, 2024
|
|
EMA-funded project to predict in-vivo mutagenicity / mutagenicity classification
|
|
9
|
1030
|
June 11, 2024
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
16
|
3509
|
June 8, 2024
|
|
A new root cause? NOx
|
|
13
|
1795
|
November 17, 2023
|
|
Formaldehyde Catalysis of Nitrosamine Formation
|
|
3
|
614
|
May 31, 2024
|
|
⚙️🌎CPCA: the gestation, birth, and development -Pub
|
|
5
|
1146
|
May 31, 2024
|
|
Genotoxicity assessments of N-nitrosoethylisopropylamine (NEIPA) and N-nitrosodiisopropylamine (NDIPA) in the C57BL/6J mouse -Pub
|
|
0
|
279
|
May 13, 2024
|
|
Are nitrosamines the connecting link or one of the connecting links between the concepts of phototoxicity and photocarcinogenicity due to the intake of a contaminated medication according to the 2019/ 2023 FDA list?
|
|
41
|
1276
|
May 11, 2024
|
|
Clinico-pathological correlations after intake of potentially nitrosamine/ NDSRIs contaminated drugs
|
|
1
|
290
|
April 14, 2024
|
|
Nitrosamines: A new systematic review
|
|
11
|
3063
|
April 14, 2024
|
|
SOT posters and talks, (shared posters -update)
|
|
3
|
797
|
April 10, 2024
|
|
1st release of Lhasa 'Complex Nitrosamines' data sharing initiative
|
|
6
|
1068
|
March 31, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
718
|
March 28, 2024
|
|
Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs) -Pub
|
|
17
|
2707
|
March 28, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
497
|
March 13, 2024
|
|
Role of Carbonyl Compounds for N-Nitrosamine Formation during Nitrosation: Kinetics and Mechanisms
|
|
0
|
399
|
March 2, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
408
|
February 24, 2024
|
|
In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products -Pub
|
|
0
|
528
|
February 8, 2024
|
|
Metabolic activation of short-chain alkyl N-nitrosamines using Aroclor 1254 or phenobarbital/beta-naphthoflavone-induced rat or hamster S9 – a comparative analysis -Pub
|
|
4
|
461
|
February 2, 2024
|